Drugs in Dev. Neurology
Phase III
Sweden 
CHMP Issues Positive Recommendation for Approval of Lecanemab in the EU
Details : Leqembi (lecanemab) is an IgG1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid-beta. It is being investigated for the treatment of early Alzheimer’s disease.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
November 14, 2024
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US
Details : Sedaconda (isoflurane) is an inhalation anesthetic that acts as a GABAA receptor modulator, decreasing motor function and inhibiting excitatory neurotransmission via NMDA receptors.
Product Name : Sedaconda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sedana Medical Receives FDA Fast Track Designation in The United States
Details : Sedaconda (isoflurane), a general inhalation anesthetic, acts as a positive allosteric GABAA receptor modulator. It enhances glycine receptor activity, which decreases motor function and inhibits NMDA glutamate receptor, which mediates excitatory neurotr...
Product Name : Sedaconda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2023
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Latest lecanemab Data to be Presented at The AD/PD™ Congress
Details : BAN2401 (lecanemab), an investigational humanized monoclonal antibody, selectively binds to, neutralize and eliminate soluble toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
November 03, 2022
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sedana Medical Submits IND for US Clinical Trials
Details : Sedaconda (isoflurane) for inhaled sedation used in combination with medical device Sedaconda ACD, it's primary endpoint in each study will is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care u...
Product Name : Sedaconda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2021
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data on Lecanemab Presented at The CTAD Alzheimer Conference
Details : Lecanemab selectively binds to, neutralize and eliminate soluble toxic Aβ aggregates (protofibrils) that are thought to contribute to the neurodegenerative process in AD.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
November 15, 2021
Latest Data on Lecanemab to be Presented at Alzheimer's Association International Conference (AAIC)
Details : The presentations will include the latest data of the investigational anti-amyloid beta (Aβ) protofibril selective antibody lecanemab (BAN2401) for which the FDA has granted Breakthrough Therapy designation.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
July 21, 2021
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sedana Medical Receives Approval for European Dossier
Details : The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.
Product Name : Sedaconda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Isoflurane
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Breakthrough Therapy Designation for Lecanemab in Alzheimer's Disease
Details : The proof-of-concept Study 201 explored the impact of treatment with lecanemab on reducing brain amyloid beta. In this study, pre-specified analysis showed consistent reduction of clinical decline across several clinical and biomarker endpoints at the hi...
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2021
Details : The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment with lecanemab on reducing brain amyloid beta (Aβ) and clinical decline in patients with early Alzheimer's disease.
Product Name : Leqembi
Product Type : Antibody
Upfront Cash : Inapplicable
April 20, 2021
Reset All
